These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 29451407)

  • 21. Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea.
    Cash BD; Lacy BE; Schoenfeld PS; Dove LS; Covington PS
    Am J Gastroenterol; 2017 Feb; 112(2):365-374. PubMed ID: 27922029
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eluxadoline for Irritable Bowel Syndrome with Diarrhea.
    Lembo AJ; Lacy BE; Zuckerman MJ; Schey R; Dove LS; Andrae DA; Davenport JM; McIntyre G; Lopez R; Turner L; Covington PS
    N Engl J Med; 2016 Jan; 374(3):242-53. PubMed ID: 26789872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eluxadoline approved for irritable bowel syndrome with diarrhea.
    Traynor K
    Am J Health Syst Pharm; 2015 Jul; 72(13):1078. PubMed ID: 26092951
    [No Abstract]   [Full Text] [Related]  

  • 24. Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use.
    Lacy BE; Chey WD; Cash BD; Lembo AJ; Dove LS; Covington PS
    Am J Gastroenterol; 2017 Jun; 112(6):924-932. PubMed ID: 28417992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improved work productivity and health-related quality of life in patients with irritable bowel syndrome with diarrhea receiving eluxadoline following inadequate response to loperamide.
    Brenner DM; Sayuk GS; Abel JL; Burslem K
    J Manag Care Spec Pharm; 2021 Apr; 27(4):469-477. PubMed ID: 33769858
    [No Abstract]   [Full Text] [Related]  

  • 26. Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome. The SEPD perspective.
    Vera I; Júdez FJ
    Rev Esp Enferm Dig; 2017 Nov; 109(11):788-794. PubMed ID: 28747053
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current and emerging pharmacological approaches for treating diarrhea-predominant irritable bowel syndrome.
    Munjal A; Dedania B; Cash BD
    Expert Opin Pharmacother; 2020 Jan; 21(1):63-71. PubMed ID: 31738621
    [No Abstract]   [Full Text] [Related]  

  • 28. Efficacy and Safety of Eluxadoline in Patients With Irritable Bowel Syndrome With Diarrhea Who Report Inadequate Symptom Control With Loperamide: RELIEF Phase 4 Study.
    Brenner DM; Sayuk GS; Gutman CR; Jo E; Elmes SJR; Liu LWC; Cash BD
    Am J Gastroenterol; 2019 Sep; 114(9):1502-1511. PubMed ID: 31356229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Management of irritable bowel syndrome with diarrhea: focus on eluxadoline.
    Jones J; Lembo A; Heidelbaugh J; Kuritzky L; Lacy B
    Curr Med Res Opin; 2021 Apr; 37(4):567-578. PubMed ID: 33566707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of Pancreatitis Following Treatment of Irritable Bowel Syndrome With Eluxadoline.
    Gawron AJ; Bielefeldt K
    Clin Gastroenterol Hepatol; 2018 Mar; 16(3):378-384.e2. PubMed ID: 28804032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials.
    Qi Q; Zhang Y; Chen F; Zuo X; Li Y
    BMC Gastroenterol; 2018 Jan; 18(1):5. PubMed ID: 29310568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women.
    Fukudo S; Kinoshita Y; Okumura T; Ida M; Akiho H; Nakashima Y; Nishida A; Haruma K
    Gastroenterology; 2016 Feb; 150(2):358-66.e8. PubMed ID: 26551550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
    Lee KJ; Kim NY; Kwon JK; Huh KC; Lee OY; Lee JS; Choi SC; Sohn CI; Myung SJ; Park HJ; Choi MK; Bak YT; Rhee PL
    Neurogastroenterol Motil; 2011 Dec; 23(12):1098-104. PubMed ID: 21920001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eluxadoline (Viberzi) for irritable bowel syndrome with diarrhea.
    Med Lett Drugs Ther; 2016 Jan; 58(1485):4-5. PubMed ID: 26714241
    [No Abstract]   [Full Text] [Related]  

  • 35. Drug discovery approaches to irritable bowel syndrome.
    Hornby PJ
    Expert Opin Drug Discov; 2015; 10(8):809-24. PubMed ID: 26193876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eluxadoline-Associated Pancreatitis in a Post-Cholecystectomy Patient: A Case Report.
    Chhaparia A; Hammami MB; Vareedayah A; Schroeder K
    Del Med J; 2017 Mar; 89(3):90-92. PubMed ID: 29894043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic considerations for drugs that treat diarrhea-predominant irritable bowel syndrome: what's new?
    Mozaffari S; Nikfar S; Abdollahi M
    Expert Opin Drug Metab Toxicol; 2024 May; 20(5):307-317. PubMed ID: 38668452
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome.
    Bruzzese E; Pesce M; Sarnelli G; Guarino A
    Expert Opin Drug Metab Toxicol; 2018 Jul; 14(7):753-760. PubMed ID: 29897844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of treatment with eluxadoline on abdominal pain in patients with IBS-D: Additional post hoc analyses of Phase 3 trials.
    Lembo AJ; Covington PS; Dove LS; Andrae DA
    Neurogastroenterol Motil; 2020 Apr; 32(4):e13774. PubMed ID: 31984655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.
    Fukudo S; Ida M; Akiho H; Nakashima Y; Matsueda K
    Clin Gastroenterol Hepatol; 2014 Jun; 12(6):953-9.e4. PubMed ID: 24315882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.